Lihong Shi

发表

Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase Inhibitor

Biching Sang, P. Farrell, Lihong Shi, 2013, Molecular Cancer Therapeutics.

Structure-based design of pyridopyrimidinediones as dipeptidyl peptidase IV inhibitors.

S. L. Gwaltney, Lihong Shi, R. Skene, 2012, Bioorganic & medicinal chemistry letters.

Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors.

D. Kassel, S. L. Gwaltney, Lihong Shi, 2008, Bioorganic & medicinal chemistry letters.

Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.

D. Kassel, S. L. Gwaltney, K. Aertgeerts, 2011, Journal of medicinal chemistry.

Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).

V. Feher, J. Yano, J. Zalevsky, 2016, Bioorganic & medicinal chemistry letters.

Design and synthesis of orally available MEK inhibitors with potent in vivo antitumor efficacy.

Lihong Shi, L. Zhang, Petro Halkowycz, 2012, Bioorganic & medicinal chemistry letters.

Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.

J. Veal, D. Hosfield, Jiangchun Xu, 2018, Bioorganic & medicinal chemistry letters.

Structure-based design and synthesis of pyrrole derivatives as MEK inhibitors.

C. Mol, V. Feher, Lihong Shi, 2010, Bioorganic & medicinal chemistry letters.

Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1).

J. Veal, D. Hosfield, L. Lawton, 2020, Journal of medicinal chemistry.

Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.

J. Veal, Jiangchun Xu, J. D. Del Rosario, 2019, Bioorganic & medicinal chemistry letters.

Design and synthesis of orally available MEK inhibitors with potent in vivo antitumor efficacy.

Lihong Shi, L. Zhang, Petro Halkowycz, 2012, Bioorganic & medicinal chemistry letters.

Rational discovery of a highly novel and selective mTOR inhibitor.

Matthew A. Lardy, P. Vincent, S. Mikami, 2019, Bioorganic & medicinal chemistry letters.

Structural and Kinetic Analysis of the Substrate Specificity of Human Fibroblast Activation Protein α*

K. Aertgeerts, Lihong Shi, A. Jennings, 2005, Journal of Biological Chemistry.

A new and direct approach to functionalized biaryl α-ketophosphonic acids via aqueous Suzuki coupling on solid support

C. Holmes, Liang Wang, M. Navre, 2006 .

Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer.

Lihong Shi, Petro Halkowycz, D. Dougan, 2011, Bioorganic & medicinal chemistry letters.

Malonyl α-mercaptoketones and α-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors

J. Skotnicki, J. Levin, M. Navre, 1998 .

Time-dependent inhibition of PHD2

Lihong Shi, C. Grimshaw, J. Ermolieff, 2017, Bioscience reports.

Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism

H. Ueno, K. Takeuchi, Lihong Shi, 2016, PloS one.

Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.

D. Kassel, K. Takeuchi, Lihong Shi, 2008, European journal of pharmacology.

Structure-based design and discovery of potent and selective KDM5 inhibitors.

J. Veal, D. Hosfield, Jiangchun Xu, 2018, Bioorganic & medicinal chemistry letters.

N‐linked glycosylation of dipeptidyl peptidase IV (CD26): Effects on enzyme activity, homodimer formation, and adenosine deaminase binding

Sheng Ye, David R Webb, Biching Sang, 2004, Protein science : a publication of the Protein Society.

Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models.

J. Veal, T. Bonaldi, D. Hosfield, 2017, ACS medicinal chemistry letters.

On Ternary Complex Stability in Protein Degradation: In Silico Molecular Glue Binding Affinity Calculations

Dahlia R. Weiss, A. Bortolato, V. Shanmugasundaram, 2023, J. Chem. Inf. Model..

Targeting Oncoproteins for Degradation by Small Molecule-Based Proteolysis-Targeting Chimeras (PROTACs) in Sex Hormone-Dependent Cancers

Yongxia Zhu, Hongtao Xiao, Lihong Shi, 2022, Frontiers in Endocrinology.

Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.

D. Kassel, S. L. Gwaltney, K. Takeuchi, 2007, Journal of medicinal chemistry.

Interaction between C 2 ORF 68 and HuR in human colorectal cancer

Lihong Shi, T. Jiang, Yaowu Chen, 2019 .